vs
Side-by-side financial comparison of Limbach Holdings, Inc. (LMB) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Limbach Holdings, Inc. is the larger business by last-quarter revenue ($138.9M vs $129.7M, roughly 1.1× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 4.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 6.6%).
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
LMB vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $138.9M | $129.7M |
| Net Profit | $4.4M | — |
| Gross Margin | 22.4% | 98.0% |
| Operating Margin | 0.8% | -25.0% |
| Net Margin | 3.2% | — |
| Revenue YoY | 4.3% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.36 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $138.9M | — | ||
| Q4 25 | $186.9M | $129.7M | ||
| Q3 25 | $184.6M | $164.9M | ||
| Q2 25 | $142.2M | $114.4M | ||
| Q1 25 | $133.1M | $81.7M | ||
| Q4 24 | $143.7M | $74.8M | ||
| Q3 24 | $133.9M | $62.9M | ||
| Q2 24 | $122.2M | $54.1M |
| Q1 26 | $4.4M | — | ||
| Q4 25 | $12.3M | — | ||
| Q3 25 | $8.8M | $25.7M | ||
| Q2 25 | $7.8M | $-12.8M | ||
| Q1 25 | $10.2M | $-41.2M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $7.5M | $-54.8M | ||
| Q2 24 | $6.0M | $-70.4M |
| Q1 26 | 22.4% | — | ||
| Q4 25 | 25.7% | 98.0% | ||
| Q3 25 | 24.2% | 99.0% | ||
| Q2 25 | 28.0% | 98.7% | ||
| Q1 25 | 27.6% | 94.3% | ||
| Q4 24 | 30.3% | 96.6% | ||
| Q3 24 | 27.0% | 97.4% | ||
| Q2 24 | 27.4% | 96.2% |
| Q1 26 | 0.8% | — | ||
| Q4 25 | 9.4% | -25.0% | ||
| Q3 25 | 7.2% | 15.1% | ||
| Q2 25 | 7.5% | -11.1% | ||
| Q1 25 | 5.9% | -52.2% | ||
| Q4 24 | 9.1% | -81.2% | ||
| Q3 24 | 8.1% | -89.3% | ||
| Q2 24 | 6.7% | -125.1% |
| Q1 26 | 3.2% | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 4.8% | 15.6% | ||
| Q2 25 | 5.5% | -11.1% | ||
| Q1 25 | 7.7% | -50.4% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.6% | -87.1% | ||
| Q2 24 | 4.9% | -130.1% |
| Q1 26 | $0.36 | — | ||
| Q4 25 | $1.01 | $0.04 | ||
| Q3 25 | $0.73 | $0.28 | ||
| Q2 25 | $0.64 | $-0.14 | ||
| Q1 25 | $0.85 | $-0.47 | ||
| Q4 24 | $0.81 | $-0.71 | ||
| Q3 24 | $0.62 | $-0.70 | ||
| Q2 24 | $0.50 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.8M | $93.0M |
| Total DebtLower is stronger | $56.6M | — |
| Stockholders' EquityBook value | $196.3M | $114.8M |
| Total Assets | $377.0M | $605.2M |
| Debt / EquityLower = less leverage | 0.29× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $15.8M | — | ||
| Q4 25 | $11.3M | $93.0M | ||
| Q3 25 | $9.8M | $110.9M | ||
| Q2 25 | $38.9M | $75.2M | ||
| Q1 25 | $38.1M | $61.9M | ||
| Q4 24 | $44.9M | $58.5M | ||
| Q3 24 | $51.2M | $36.4M | ||
| Q2 24 | $59.5M | $32.3M |
| Q1 26 | $56.6M | — | ||
| Q4 25 | $30.5M | — | ||
| Q3 25 | $56.3M | — | ||
| Q2 25 | $28.4M | — | ||
| Q1 25 | $23.7M | — | ||
| Q4 24 | $23.6M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $19.7M | — |
| Q1 26 | $196.3M | — | ||
| Q4 25 | $195.7M | $114.8M | ||
| Q3 25 | $181.6M | $73.6M | ||
| Q2 25 | $170.5M | $32.7M | ||
| Q1 25 | $161.1M | $32.8M | ||
| Q4 24 | $153.5M | $59.1M | ||
| Q3 24 | $142.2M | $-30.5M | ||
| Q2 24 | $133.0M | $15.1M |
| Q1 26 | $377.0M | — | ||
| Q4 25 | $381.1M | $605.2M | ||
| Q3 25 | $409.1M | $538.6M | ||
| Q2 25 | $343.0M | $555.3M | ||
| Q1 25 | $336.4M | $548.8M | ||
| Q4 24 | $352.1M | $594.1M | ||
| Q3 24 | $324.4M | $504.4M | ||
| Q2 24 | $303.9M | $551.1M |
| Q1 26 | 0.29× | — | ||
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.1M | $60.7M | ||
| Q3 25 | $13.3M | $14.3M | ||
| Q2 25 | $2.0M | $5.0M | ||
| Q1 25 | $2.2M | $-42.2M | ||
| Q4 24 | $19.3M | $-35.7M | ||
| Q3 24 | $4.9M | $-42.5M | ||
| Q2 24 | $16.5M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $27.9M | — | ||
| Q3 25 | $12.8M | $14.2M | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $11.0K | — | ||
| Q4 24 | $18.0M | — | ||
| Q3 24 | $4.6M | — | ||
| Q2 24 | $13.2M | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | 14.9% | — | ||
| Q3 25 | 7.0% | 8.6% | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 12.5% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 10.8% | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.3% | 0.1% | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 2.7% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.29× | — | ||
| Q3 25 | 1.52× | 0.56× | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 1.96× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 2.77× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LMB
| ODR | $99.8M | 72% |
| GCR | $39.0M | 28% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
